1. Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022

   • Eiki Ichihara
   • Nobuaki Ochi
   • Toshio Kubo

   Special Article 14 February 2024 Pages: 355 - 362

   

2. Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021

   • Hidekatsu Nakai
   • Takahiro Higashi
   • Noriomi Matsumura

   Cancer Statistics 21 February 2024 Pages: 363 - 371

   

3. Analgesic efficacy and safety of percutaneous thermal ablation plus cementoplasty for painful bone metastases: a systematic review and meta-analysis

   • Tomohiro Matsumoto
   • Rika Yoshimatsu
   • Takuji Yamagami

   Original Article 13 January 2024 Pages: 372 - 385

   

4. Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study

   • Yuki Katsuya
   • Tatsuya Yoshida
   • Noboru Yamamoto

   Original Article Open access 21 February 2024 Pages: 386 - 397

   

5. Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study

   • Shigeki Kataoka
   • Yoshitaka Nishikawa
   • Manabu Muto

   Original Article 14 February 2024 Pages: 398 - 406

   

6. Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: a Cancer-VTE Registry subanalysis

   • Mashio Nakamura
   • Masato Sakon
   • Masataka Ikeda

   Original Article Open access 02 March 2024 Pages: 407 - 416

   

7. Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance

   • Sena Yamamoto
   • Chiharu Kondoh
   • Harue Arao

   Original Article Open access 24 February 2024 Pages: 417 - 426

   

8. Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer

   • Yang Li
   • Jun Qin
   • Xing Sun

   Original Article 27 February 2024 Pages: 427 - 441

   

9. Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression

   • Zijun Guo
   • Lin Guo

   Original Article 21 February 2024 Pages: 442 - 455

   

10. Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan

    • Junji Furuse
    • Fumihiko Osugi
    • Toshimitsu Endo

    Original Article Open access 14 February 2024 Pages: 456 - 463

    

11. Hydronephrosis severity as a predictor of postoperative renal function decline following laparoscopic radical nephroureterectomy

    • Toru Kanno
    • Go Kobori
    • Hitoshi Yamada

    Original Article 06 February 2024 Pages: 464 - 472

    

12. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data

    • Hiroki Ishihara
    • Kenji Omae
    • Toshio Takagi

    Original Article 12 February 2024 Pages: 473 - 480

    

13. Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy

    • Honami Sato
    • Takahiro Kobayashi
    • Naoto Takahashi

    Original Article Open access 09 February 2024 Pages: 481 - 492